Sun Pharmaceutical Industries has informed that the postal ballot process initiated pursuant to the notice dated 17 March 2026, wherein the voting period commenced on 19 March 2026, has been concluded today, 17 April 2026. Based on the Scrutinizer’s Report, the following resolutions as set out in the Postal Ballot Notice dated 17 March 2026 have been duly passed by the shareholders with the requisite majority and shall be deemed passed on 17 April 2026 to take effect in accordance with applicable regulatory requirements and subject to completion of statutory filings and compliance.  Ratification of the remuneration of the Cost Auditor for FY 2025–26; Alteration to Clause III(A) (Main Objects) of the Memorandum of Association; and 3. Re-appointment of Dr Pawan Goenka as an Independent Director for a second term of five years, effective from 21 May 2026. The Voting Results have been filed by the Company in XBRL mode, and the Scrutinizer Report is made available on the Company’s website at www.sunpharma.com.